Trial · NCT02730377
Results by group110
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 110
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Inadequate Glycaemic Control | Liraglutide 1.8 mg | 108.9 | Inter-Quartile Range 37.7 to NA | Weeks | |
| Time to Inadequate Glycaemic Control | Oral Antidiabetic Drug | 64.9 | Inter-Quartile Range 35.4 to 107.4 | Weeks | |
| Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control) | Liraglutide 1.8 mg | 80.4 | Inter-Quartile Range 35.7 to NA | Weeks | |
| Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control) | Oral Antidiabetic Drug | 52.3 | Inter-Quartile Range 35.1 to NA | Weeks | |
| Change in HbA1c | Liraglutide 1.8 mg | Change at week 104 | -1.4 | Standard Deviation 1.06 | Percentage point of HbA1c |
| Change in HbA1c | Oral Antidiabetic Drug | Change at week 104 | -1.1 | Standard Deviation 1.04 | Percentage point of HbA1c |
| Change in HbA1c | Liraglutide 1.8 mg | Change at premature treatment discontinuation | -0.6 | Standard Deviation 1.03 | Percentage point of HbA1c |
| Change in HbA1c | Oral Antidiabetic Drug | Change at premature treatment discontinuation | -0.2 | Standard Deviation 1.56 | Percentage point of HbA1c |
| Participants Who Achieve HbA1c ≤6.5% (Yes/No) | Liraglutide 1.8 mg | Yes | 255 | Participants | |
| Participants Who Achieve HbA1c ≤6.5% (Yes/No) | Oral Antidiabetic Drug | Yes | 162 | Participants | |
| Participants Who Achieve HbA1c ≤6.5% (Yes/No) | Liraglutide 1.8 mg | No | 741 | Participants | |
| Participants Who Achieve HbA1c ≤6.5% (Yes/No) | Oral Antidiabetic Drug | No | 833 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Weight Gain | Liraglutide 1.8 mg | Yes | 329 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Weight Gain | Oral Antidiabetic Drug | Yes | 234 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Weight Gain | Liraglutide 1.8 mg | No | 667 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Weight Gain | Oral Antidiabetic Drug | No | 761 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes | Liraglutide 1.8 mg | Yes | 388 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes | Oral Antidiabetic Drug | Yes | 292 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes | Liraglutide 1.8 mg | No | 608 | Participants | |
| Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes | Oral Antidiabetic Drug | No | 703 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02730377/results